Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

254 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J, Laharie D, Michiels C, Flamand M, Bouguen G, Nancey S, Presles E, Paul S, Schneider S, Hébuterne X, Roblin X. Filippi J, et al. Among authors: laharie d. J Crohns Colitis. 2015 Mar;9(3):252-8. doi: 10.1093/ecco-jcc/jjv001. Epub 2015 Jan 14. J Crohns Colitis. 2015. PMID: 25588386
Infliximab plus azathioprine for steroid-dependent Crohn's disease patients: a randomized placebo-controlled trial.
Lémann M, Mary JY, Duclos B, Veyrac M, Dupas JL, Delchier JC, Laharie D, Moreau J, Cadiot G, Picon L, Bourreille A, Sobahni I, Colombel JF; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif (GETAID). Lémann M, et al. Among authors: laharie d. Gastroenterology. 2006 Apr;130(4):1054-61. doi: 10.1053/j.gastro.2006.02.014. Gastroenterology. 2006. PMID: 16618399 Clinical Trial.
The efficacy and safety of a third anti-TNF monoclonal antibody in Crohn's disease after failure of two other anti-TNF antibodies.
Allez M, Vermeire S, Mozziconacci N, Michetti P, Laharie D, Louis E, Bigard MA, Hébuterne X, Treton X, Kohn A, Marteau P, Cortot A, Nichita C, van Assche G, Rutgeerts P, Lémann M, Colombel JF. Allez M, et al. Among authors: laharie d. Aliment Pharmacol Ther. 2010 Jan;31(1):92-101. doi: 10.1111/j.1365-2036.2009.04130.x. Aliment Pharmacol Ther. 2010. PMID: 19709098 Free article.
A multicenter experience with infliximab for ulcerative colitis: outcomes and predictors of response, optimization, colectomy, and hospitalization.
Oussalah A, Evesque L, Laharie D, Roblin X, Boschetti G, Nancey S, Filippi J, Flourié B, Hebuterne X, Bigard MA, Peyrin-Biroulet L. Oussalah A, et al. Among authors: laharie d. Am J Gastroenterol. 2010 Dec;105(12):2617-25. doi: 10.1038/ajg.2010.345. Epub 2010 Aug 24. Am J Gastroenterol. 2010. PMID: 20736936
Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.
Laharie D, Bourreille A, Branche J, Allez M, Bouhnik Y, Filippi J, Zerbib F, Savoye G, Nachury M, Moreau J, Delchier JC, Cosnes J, Ricart E, Dewit O, Lopez-Sanroman A, Dupas JL, Carbonnel F, Bommelaer G, Coffin B, Roblin X, Van Assche G, Esteve M, Färkkilä M, Gisbert JP, Marteau P, Nahon S, de Vos M, Franchimont D, Mary JY, Colombel JF, Lémann M; Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. Laharie D, et al. Lancet. 2012 Dec 1;380(9857):1909-15. doi: 10.1016/S0140-6736(12)61084-8. Epub 2012 Oct 10. Lancet. 2012. PMID: 23063316 Clinical Trial.
254 results